Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels

Periodontal Diseases Clinical Trial

— hbD2  

Official title:

The Effect of Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04946617
• Other study ID #: 9.2.2017-30
• Status: Not yet recruiting
• Start date: July 20, 2021
• Est. completion date: December 20, 2021

Study information

• Verified date: June 2021
• Source: Istanbul Medeniyet University
• Contact: Mustafa C Yavuz, PhD
• Phone: +905056429856
• Email: muscyz111[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Recent studies have shown that while mouthwashes exhibit antimicrobial properties against bacteria and their products, at the same time showing the cytotoxic effect on living cells in the mouth.29 To the best of our knowledge, there is no information about the toxicity effect of these two mouthwashes, which are highly preferred, on antimicrobial peptides secreted from the oral epithelium. Therefore, our aim in this study is to evaluate the effect of chlorhexidine and essential oil mouthwash on hBD2 and LL-37 in saliva.

Description:

Periodontal health continues with a balanced interaction of the oral microflora with the host defense line.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: December 20, 2021
• Est. primary completion date: December 20, 2021
• Gender: All
• Age group: 25 Years to 40 Years

Eligibility

Inclusion Criteria:

1. systemically healthy,

2. presence of =20 natural teeth,

3. agreement to participate in the study .

Exclusion Criteria:

1. known systemic illness,

2. smoking habit,

3. pregnancy/ lactation,

4. long-term use of anti-inflammatory drugs.

Related Conditions & MeSH terms

• Gingivitis
• Mouth and Tooth Diseases
• Periodontal Diseases
• Stomatognathic Diseases
• Tooth Diseases

Intervention

Drug:
• undefined
Rinsing with mouthwashes

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul Medeniyet University

References & Publications (1)

Van Dyke TE. Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med. 2017 Dec;58:21-36. doi: 10.1016/j.mam.2017.04.006. Epub 2017 May 18. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of periodontal parametres changes	Incidence of Gingivitis	6 Months
Primary	Rate of periodontal parametres changes	Incidence of Periodontitis	6 Months